Aripiprazole Lauroxil
Schizoaffective Disorder, Depressive Type
University of California, Los AngelesSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizoaffective Disorder, Depressive Type cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Al-Ncd University of California, Los Angeles | Phase 4 | B |
Same molecule, other indications
Aripiprazole Lauroxil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →